Government-Owned Invention; Availability for Licensing, 75832 [2016-26260]

Download as PDF 75832 Federal Register / Vol. 81, No. 211 / Tuesday, November 1, 2016 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Invention; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496– 2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished scientific data. SUPPLEMENTARY INFORMATION: Technology description follows. SUMMARY: asabaliauskas on DSK3SPTVN1PROD with NOTICES A Human Progenitor Mast Cell Line for Allergic and Fibrotic Research and Therapeutic Screening Description of Technology: Hermansky-Pudlak Syndrome type-1 (HPS-1) is a rare genetic disorder that affects around 1 in 500,000 people worldwide and 1 in 1,800 Puerto Ricans. Patients with HPS-1 display oculocutaneous albinism, bleeding due to platelet abnormality, and pulmonary fibrosis. Those that develop pulmonary fibrosis often succumb and live no more than a decade after early onset of breathing problems. Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) have developed the HPS-1 proMastocyte (HPM) cell line, containing an HPS-1 mutation. This cell line resembles a progenitor mast cell with reduced granule formation, significant chemotactic ability, and is the first mast cell line shown to constitutively release cytokines, chemokines, and most importantly fibrotic proteins. This cell line serves as a model to study granule formation, early mast cell development, chemotaxis and mechanisms controlling synthesis of molecules contributing to fibrosis. VerDate Sep<11>2014 00:01 Nov 01, 2016 Jkt 241001 The cell line is available as live cells approximately 3–4 million cells per sample in a T25 Flask. Potential Commercial Applications: • A tool to further understand fibrosis • A tool to study granule formation, early mast cell development, degranulation and chemotaxis • Screening tool to identify target compounds for the treatment of pulmonary fibrosis Competitive Advantages: • First progenitor mast cell line known to produce fibrotic elements • Progenitor mast cell line with rapid growth, no cytokine stimulation needed. Cell doubling time of 2–3 days Inventors: Arnold S. Kirchenbaum and Dean D.Metcalfe, both of NIAID. Publications: Kirshenbaum AS et al. Immunophenotypic and Ultrastructural Analysis of Mast Cells in Hermansky-Pudlak Syndrome Type-1: A Possible Connection to Pulmonary Fibrosis.; PLoS One. 2016, Jul 26;11(7):e0159177, PMID 27459687 Intellectual Property: HHS Reference No. E–270–2016/0. Available as a Biological Material. Licensing Contact: Dr. Benjamin Hurley, (240) 669–5092, benjamin.hurley@nih.gov. Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this invention. For collaboration opportunities, please contact Dr. Dianca Finch; 240– 669–5503, dianca.finch@nih.gov. Dated: October 26, 2016. Suzanne Frisbie, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2016–26260 Filed 10–31–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the Frederick National Laboratory Advisory Committee to the National Cancer Institute, November 16, 2016, 01:00 p.m. to November 16, 2016, 05:30 p.m., National Cancer Institute PO 00000 Frm 00028 Fmt 4703 Sfmt 4703 Advanced Technology Research Facility (ATRF), 8560 Progress Drive, Auditorium Room E1600, Frederick, MD, 21702 which was published in the Federal Register on October 24, 2016, 81 FR 73119. This Notice has been amended to change the: Meeting date; start and end times; agenda and type of meeting. The meeting will now be held on November 16, 2016 from 8:00 a.m. to November 17, 2017, 12:00 p.m. to conduct a site visit of the Frederick National Laboratory for Cancer Research and the National Cancer Institute (NCI) RAS Initiative. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The project/program and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the project/ program, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Dated: October 26, 2016. Melanie J. Gray, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–26259 Filed 10–31–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel, Animal Assisted Intervention Review. Date: December 5, 2016. Time: 8:00 a.m. to 8:00 p.m. E:\FR\FM\01NON1.SGM 01NON1

Agencies

[Federal Register Volume 81, Number 211 (Tuesday, November 1, 2016)]
[Notices]
[Page 75832]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-26260]



[[Page 75832]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Invention; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing in the U.S. in accordance 
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by communicating with the indicated licensing contact at the Technology 
Transfer and Intellectual Property Office, National Institute of 
Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 
20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement 
will be required to receive copies of unpublished scientific data.

SUPPLEMENTARY INFORMATION: Technology description follows.

A Human Progenitor Mast Cell Line for Allergic and Fibrotic Research 
and Therapeutic Screening

    Description of Technology: Hermansky-Pudlak Syndrome type-1 (HPS-1) 
is a rare genetic disorder that affects around 1 in 500,000 people 
worldwide and 1 in 1,800 Puerto Ricans. Patients with HPS-1 display 
oculocutaneous albinism, bleeding due to platelet abnormality, and 
pulmonary fibrosis. Those that develop pulmonary fibrosis often succumb 
and live no more than a decade after early onset of breathing problems.
    Scientists at the National Institute of Allergy and Infectious 
Diseases (NIAID) have developed the HPS-1 proMastocyte (HPM) cell line, 
containing an HPS-1 mutation. This cell line resembles a progenitor 
mast cell with reduced granule formation, significant chemotactic 
ability, and is the first mast cell line shown to constitutively 
release cytokines, chemokines, and most importantly fibrotic proteins. 
This cell line serves as a model to study granule formation, early mast 
cell development, chemotaxis and mechanisms controlling synthesis of 
molecules contributing to fibrosis.
    The cell line is available as live cells approximately 3-4 million 
cells per sample in a T25 Flask.
    Potential Commercial Applications:

 A tool to further understand fibrosis
 A tool to study granule formation, early mast cell 
development, degranulation and chemotaxis
 Screening tool to identify target compounds for the treatment 
of pulmonary fibrosis

    Competitive Advantages:

 First progenitor mast cell line known to produce fibrotic 
elements
 Progenitor mast cell line with rapid growth, no cytokine 
stimulation needed. Cell doubling time of 2-3 days

    Inventors: Arnold S. Kirchenbaum and Dean D.Metcalfe, both of 
NIAID.
    Publications:

Kirshenbaum AS et al. Immunophenotypic and Ultrastructural Analysis of 
Mast Cells in Hermansky-Pudlak Syndrome Type-1: A Possible Connection 
to Pulmonary Fibrosis.; PLoS One. 2016, Jul 26;11(7):e0159177, PMID 
27459687

    Intellectual Property: HHS Reference No. E-270-2016/0. Available as 
a Biological Material.
    Licensing Contact: Dr. Benjamin Hurley, (240) 669-5092, 
benjamin.hurley@nih.gov.
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate or commercialize this invention.
    For collaboration opportunities, please contact Dr. Dianca Finch; 
240-669-5503, dianca.finch@nih.gov.

    Dated: October 26, 2016.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2016-26260 Filed 10-31-16; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.